Clinical trials: Bloodstream Infections
Candidiasis
Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis
The purpose of this study is to further evaluate the safety and effectiveness of intravenous anidulafungin (Eraxis™) in patients with a diagnosis of candidemia or invasive candidiasis, which is a fungus infection of the blood or…
- Trial name
- NCT00496197
- Testing
- Eraxis (anidulafungin), Diflucan (fluconazole), Vfend (voriconazole)
- Where
- 43 sites in United States, South Korea
- Volunteers
- 282 people
- Sponsor
- Pfizer
Bacteremia
Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA
In vitro identification of S. aureus,methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA)from positive blood culture using MicroPhage's bacteriophage-based diagnostic platform.
- Trial name
- NCT01640886
- Where
- 3 sites in United States
- Volunteers
- 764 people
- Sponsor
- MicroPhage, Inc.
Sepsis, Septic Shock
Combined Hemoperfusion and Therapeutic Plasma Exchange for Treatment of Patients With Septic Shock
Sepsis is a critical burden for a healthcare. From 2000 to 2020, the number of publications and clinical studies on the topic of Sepsis and septic shock on the National Library of Medicine resource The National Center for…
- Trial name
- NCT06404424
- Testing
- Efferon LPS, Efferon CT
- Where
- Russia
- Volunteers
- 82 people
- Sponsor
- Efferon JSC
Sepsis
Biomarker-enhanced Artificial Intelligence Based Pediatric Sepsis Screening Tool
The overall objective of this proposed research is the derivation of a biomarker-enhanced artificial intelligence (AI)-based pediatric sepsis screening tool (PSCT) (software) that can be used in combination with the hospital's…
- Trial name
- NCT05311046
- Testing
- Pediatric sepsis screening tool (either algorithmic or manual)
- Where
- United States
- Volunteers
- 12,961 people
- Sponsor
- Computer Technology Associates, Inc.
Sepsis
Changes in Exhaled 13CO2/12CO2 Breath Delta Value as an Early Indicator of Infection in ICU Patients
Carbon-12 and carbon-13 are naturally-abundant isotopes in exhaled breath carbon dioxide. The ratio of carbon-13 to carbon-12 in exhaled breath is known as the breath delta value (BDV).
- Trial name
- NCT02327130
- Testing
- Isomark Canary™
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Isomark, LLC
Bacteremia
Ceftobiprole in the Treatment of Hospitalized Patients With Staphylococcus Aureus Bacteremia
The purpose of this study is to assess the safety and efficacy of ceftobiprole versus a comparator in hospitalized patients with bacteremia.
- Trial name
- NCT00505258
- Testing
- ceftobiprole medocaril
- Sponsor
- Basilea Pharmaceutica
Sepsis, Septicemia
A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning
In this study, the investigators will deploy a software-based clinical decision support tool (eCARTv5) into the electronic health record (EHR) workflow of multiple hospital wards.
- Conditions
- Sepsis, Septicemia, Respiratory Failure, Hemodynamic Instability
- Trial name
- NCT05893420
- Testing
- eCARTv5 clinical deterioration monitoring, Standard of care control
- Where
- 3 sites in United States
- Volunteers
- 30,000 people
- Sponsor
- AgileMD, Inc.
LRTI, UTI
Observational, Prospective Clinical Study to Evaluate Biomarkers as Indicators of Acute Bacterial or Viral Infections
This is an observational prospective study of an in-vitro diagnostic (IVD) assay planned to enroll 632 subjects. The study will be conducted in two stages: Stage A is aimed at identifying individual biomarkers and constructing a…
- Conditions
- LRTI, UTI, Gastroenteritis, Systemic Infections/Bacteremia/Meningitis
- Trial name
- CURIOSITY (NCT01917461)
- Where
- 2 sites in Israel
- Volunteers
- 1,001 people, healthy volunteers welcome
- Sponsor
- MeMed Diagnostics Ltd.
Septic Shock
ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber
The primary objective of this clinical investigation is to investigate the feasibility and possible benefits of the Alteco® LPS Adsorber in treating patients with septic shock with presumed endotoxemia of abdominal or urogenital…
- Trial name
- ASSET (NCT02335723)
- Testing
- Alteco LPS Adsorber
- Where
- 6 sites in Finland, Norway and 1 more
- Volunteers
- 15 people
- Sponsor
- Alteco Medical AB
Sepsis-Induced Hypotension
A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension
This study is researching an experimental drug called REGN7544 (called "study drug"). The study is focused on adult patients (18 to 85 years) hospitalized due to a serious infection (called "sepsis") and receiving…
- Trial name
- ESTELLA (NCT06608901)
- Testing
- REGN7544, PB
- Where
- 29 sites in United States, France
- Volunteers
- 76 people
- Sponsor
- Regeneron Pharmaceuticals
Acute Pancreatitis With Uninfected Necrosis, Unspecified
Hemoperfusion Efferon СT for the Treatment of Patients With Acute Pancreatitis
Mortality from severe acute pancreatitis reaches 42%. The prognosis of acute pancreatitis is associated with the development of acute inflammatory response syndrome (SIRS) and multiple organ failure (MOF).
- Trial name
- NCT05695001
- Testing
- Efferon CT
- Where
- Russia
- Volunteers
- 34 people
- Sponsor
- Efferon JSC
Bacteremia Sepsis
Resistell Phenotech AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing Bacteremia
The aim of this study is to assess the sensitivity, specificity, and accuracy of the Resistell Phenotech device in testing antibiotic susceptibility of Gram-negative bacteria (i.e., E. coli or K.
- Trial name
- PHENOTECH-1 (NCT05613322)
- Testing
- Resistell Phenotech
- Where
- 3 sites in Austria, Spain and 1 more
- Volunteers
- 246 people
- Sponsor
- Resistell AG
Septic Shock, Endotoxemia
Open-label Evaluation of Polymyxin B Hemoperfusion for Septic Shock
Open-label, non-controlled study of standard care plus the TORAYMYXIN PMX-20R (PMX cartridge) in subjects who have endotoxemia and septic shock.
- Trial name
- EUPHORIA (NCT02825329)
- Testing
- TORAYMYXIN PMX-20R
- Sponsor
- Spectral Diagnostics (US) Inc.
Respiratory Distress Syndrome, Adult
Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS
This Phase IIa pilot study is a placebo controlled, multicenter study to evaluate safety and efficacy of aerosolized BIO-11006 Inhalation Solution in ARDS patients.
- Trial name
- NCT03202394
- Testing
- BIO-11006
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- BioMarck Pharmaceuticals, Ltd.
Sepsis, Septic Shock
Clearance of Antibacterial Agents During Hemoperfusion in Patients With Sepsis
One of the significants health problems in the world is sepsis, with the number of cases reaching 20-30 million per year, according to the WHO.
- Trial name
- NCT06602245
- Where
- 4 sites in Russia
- Volunteers
- 30 people
- Sponsor
- Efferon JSC
Staphylococcus Aureus Bacteremia
Clinical Trial Comparing Safety and Pharmacokinetics of Standard Antibiotic Therapy, Plus Aurexis® or Placebo, for Treatment of Staphylococcus Aureus Bacteremia (SAB)
Hospitalized patients at least 18 years of age, with Staphylococcus aureus bacteremia (SAB) will be enrolled into the study and receive one dose of Aurexis® intravenously on Study Day 1, and will be followed until Study Day 57.
- Trial name
- NCT00198302
- Testing
- Aurexis®
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Sepsis
Single-dose/Multiple-doses Incremental Intravenous Injection of SY-005 （Recombinant Human Annexin A5）in Healthy Subjects
This is a single-dose/multiple-doses incremental, randomized, double-blind, parallel, placebo-controlled study on safety, tolerance and pharmacokinetics healthy subjects.
- Trial name
- NCT04217629
- Testing
- SY-005
- Where
- China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Suzhou Yabao Pharmaceutical R&D Co., Ltd.
Acute Kidney Injury Due to Sepsis
(Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI
Clinical phase 3 study to investigate the effect of recAP on 28 day mortality in patients admitted to the ICU with acute kidney injury that is caused by sepsis. The study has three distinct SA-AKI trial populations: 1.
- Trial name
- NCT04411472
- Testing
- Recombinant human alkaline phosphatase
- Where
- 122 sites in United States, Australia and 13 more
- Volunteers
- 676 people
- Sponsor
- AM-Pharma
Acute Kidney Injury, Septic Shock
Targeting Abdominal Perfusion Pressure in Septic Shock
A randomized control trial among patients with septic shock, studying the incidence, progression and recovery of AKI.
- Conditions
- Acute Kidney Injury, Septic Shock, Resuscitations
- Trial name
- MAP-APP (NCT03582046)
- Testing
- Abdominal Perfusion Pressure (APP), Mean Arterial Pressure (MAP)
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Potrero Medical
Catecholamine Resistant Hypotension (CRH), Distributive Shock
Expanded Access for LJPC-501
The primary objective of the study is to provide access to LJPC-501 for distributive shock patients who remain hypotensive despite receiving fluid and vasopressor therapy.
- Conditions
- Catecholamine Resistant Hypotension (CRH), Distributive Shock, High Output Shock, Sepsis
- Trial name
- NCT03245528
- Testing
- LJPC-501
- Sponsor
- La Jolla Pharmaceutical Company